TCT-825 In-Vivo Long Term Evaluation of a Novel Mitral Valve Regurgitation Therapy: Experience in a Preclinical Large Animal Model  by Peppas, Athanasios et al.
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PM
P
O
S
T
E
R
SVEGF-B could be an ideal candidate as therapy of dilated cardiomyopathy which
is characterized by an increased rate of apoptosis and cardiac remodeling. The aim
of this current pre-clinical large animal study was to determine if antegrade gene
therapy with VEGF-B can help to prevent the onset of pacing-induced
cardiomyopathy.
Methods: The possible effects of VEGF-B gene therapy were tested in 23
chronically instrumented dogs with tachypacing-induced dilated cardiomyopathy
and a pacing protocol of four weeks. Thirteen subjects received at least 10^13
AAV-9-VEGF-B167 genes intracoronarily administered with a 2.5F micro-infusion
catheter selectively into the LAD at the beginning of the pacing protocol. Ten dogs
received 10^13 AAV9-GFP instead and served as control group. Gene transduction
efﬁcacy was measure by GFP-staining after the completion of the protocol.
Hemodynamic changes and echocardiography were compared at baseline and after
28days of pacing.
Results: Gene transfer procedures were successful in all animals. The GFP-infection
rate of cardiomyocytes varied widely from 1%-50% with heterogeneous distribution
between subendocardial, midventricular and subepicardial layers. But the VEGF-B
treatment helped to preserve cardiac function signiﬁcantly compared to the GFP
control group thus LV end-diastolic pressure was 12.33.6 vs. 23.334.1mmHg, dP/
dtmax 2432732 vs. 1461548mmHg/sec and ejection fraction 48.24.8 vs.
30.45.4% (all P<0.05). We were able to identify a reduction of oxidative stress in
vivo and in vitro as possible mechanism of cardiprotection of VEGF-B in addition to
the known anti-apoptotic capacity in the treatment group.
Conclusions: These results, obtained with a clinical applicable interventional
approach in an established animal model of heart failure, support that VEGF-
B167 gene therapy is highly effective as new therapy for non-ischemic heart
failure.TCT-823
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Background: Meta-analysis suggest that intracoronary (IC) administration of
autologous bone marrow mononuclear cells (BMCs) delivered early after acute
myocardial infarction (MI) may improve left ventricular (LV) function. However,
many patients early post MI are unstable or present to sites without cell delivery
capabilities, and it is unknown if changes in the myocardium or bone marrow will
alter the homing and engraftment of BMCs when delivered several weeks post-MI.
LateTIME was a randomized, double-blind, placebo-controlled trial sponsored by
the National Heart, Lung and Blood Institute (NHLBI) and CCTRN to investigate
safety and therapeutic efﬁcacy of IC BMCs delivered 2-3 weeks following
successful reperfusion with primary PCI in patients with new post-MI LV
dysfunction. At 6 months, LVEF improved in both groups with no signiﬁcant
difference between groups but with a trend for improvement in clinical events in
BMC-treated patients (5%) vs. placebo (17%). We will report the 2-year MRI and
clinical results.
Methods: A total of 87 (72 M, 15 F) age 5711 underwent bone marrow
aspiration and isolation of BMCs using standardized automated system (Sepax
device, Biosafe SA) followed by IC infusion of 150 million BMCs or cell-free
solution (2:1 BMC:Placebo) within 12 hours of bone marrow harvest in a blinded
fashion at 5 CCTRN sites and their satellites between September 2008 and
February 2011. Changes in global and regional LV function by cardiac MRI were
assessed at 6 months (1 endpoint) as well as 1 and 2 years, in addition to clinical
events
Results: Results will be presented at TCT 2013.
Conclusions: In the LateTIME trial, patients treated 2-3 weeks post MI had no
signiﬁcant improvement in LV global or regional function at 6 months withJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstra trend for reduction in clinical events complete and ﬁnal. Two-year global and
regional function as well as clinical events will be presented for the LateTIME
trial.TCT-824
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Background: Drug-eluting stents markedly reduce restenosis; however, re-endothe-
lialization is delayed. Integrin-binding cyclic Arg-Gly-Asp (cRGD) peptide-loaded
stents offer potential for enhanced early and late endothelial recovery by endothelial
progenitor cell (EPC) anchorage. Here, a novel dual cRGD and everolimus-eluting
stent was compared to an everolimus-eluting stent.
Methods: The porcine 10% coronary overstretch model was employed for analysis of
Multi-Link Tetra bare metal stents with or without a speciﬁc adherent, conformal,
mechanically robust polymer coating based on an aromatic polyetherurethaneurea
with a soft segment of polytetramethyleneoxide and a hard segment of diphenyl-
methane diisocyanate and mixed diamines covered by a control-release layer. Stents
were coated with immobilized cRGD, everolimus or cRGD + everolimus on the
biostable PEA-40 polymer surface coating. Isolated porcine EPCs were labeled with
cell tracker CM-DiI and infused into coronary arteries immediately after stent
implantation. cRGD or everolimus recovered mass were analyzed by mass spec-
troscopy, the luminal area was inspected by en face ﬂuorescence microscopy or
scanning electron microscopy for re-endothelialization and area stenosis was
quantiﬁed.
Results: cRGD and everolimus recovered mass from PEA-40 cRGD/everolimus
stents showed a slow release proﬁle. EPC recruitment to stents was evidenced after
intracoronary infusion of ﬂuorescence-labeled EPCs. In cRGD + everolimus loaded
stents, in-stent cross sectional stenosis was reduced and re-endothelialization above
stent struts was accelerated (p<0.05 for both) while re-endothlialization between
struts was similar (p>0.05) as compared to both everolimus-loaded and bare-metal
stents.
Conclusions: PEA40 is a reliable carrier for cRGDand everolimus. cRGD+everolimus
coated stents decrease coronary stenosis and promote endothelialization compared to
everolimus-eluting stents. Dual-loaded stents combine accelerated integrin-dependent
endothelial strut coverage with everolimus-dependent stenosis reduction. Vascular
healing by distinct homing of circulating EPCs and antiproliferatory properties of
everolimus concertedly act to improve stent safety and efﬁcacy.TCT-825
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Background: The MitraSpacer (Cardiosolutions, Inc.) is a novel approach to
address mitral regurgitation by introducing a dynamic spacer with characteristics that
constantly adjust to the instantaneous hemodynamics of the mitral apparatus and left
atrium (LA). The purpose of this study was to evaluate the safety of the MitraSpacer
within the mitral valve apparatus in the domestic swine model.
Methods: Five (5) domestic swine were enrolled in this study. Through a left
thoracotomy, the shaft of the MitraSpacer was introduced through the left
ventricular (LV) apex and advanced in to the left atrium avoiding the chordae ten-
dineae. Once the device was in place, the balloon located in the distal portion of the
shaft was partially ﬁlled with an iopromide/saline mix introduced by a subcutaneous
access port to the desired volume. After implantation, all animals were survived up to
90 days and heart and device were examined for further histological analysis.
Results: Following implantation, device performance was assessed by ﬂuoroscopy
and echocardiography. The volume within the balloon shifted during the cardiac cycle
in all cases following the direction of blood ﬂow and applied pressure. All enrolled
animals survived up to 90 days for terminal imaging and tissue harvest. Echo data
showed no change in LV ejection fraction from baseline to 90 days, 60.64.7% and
65.77.8% (p¼0.34) respectively, and slight changes in LA and LV volumes
consistent with the rate of growth of the animal over time. In addition, there were no
observations of disruption in LV diastolic function, pulmonary vein inﬂow, or
tricuspid regurgitation. The histological analysis demonstrated minimal impact to the
mitral apparatus despite constant contact with the device, and no evidence of
thromboembolism in the heart and peripheral organs.
Conclusions: In a healthy animal model, the long term placement of the
MitraSpacer was feasible, maintained cardiac performance and caused no structural
changes to the mitral apparatus over 90 days.acts/POSTER/Basic Science, Animal Models, and Cell Therapy B249
